Two weeks ago, Dr. Reddy’s Laboratories released a very brief statement that the Food and Drug Administration had found some problems with a key plant where the drug maker hopes to produce several generic cancer medications. At the time, though, there were no details, but now the inspection report is available and the infractions do not appear to bode well for the company.

During their visit last month to the facility in Visakhapatnam, India, FDA inspectors found what are called multiple repeat observations of various problems, which is regulatory parlance for manufacturing gaffes that were noted during previous inspections. In fact, half of the quality control problems that were seen had been spotted when FDA staff visited more than a year earlier.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Maybe the FDA should let patients report minor illnesses while taking drugs from factories that have had warnings. That way inspectors might be able to directly track patient reported infections (UTI, fungal, rash) to the shoddy conditions they observed and put careless owners out of biz.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy